Related Experiment Video

Updated: May 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Cardiometabolic impact of non-statin lipid lowering therapies

Parag Goyal1, Leon I Igel, Keith LaScalea

  • 1, 402 East 67th Street, New York, NY, 10065, USA.

Current Atherosclerosis Reports
|January 8, 2014
PubMed

Insights

This review examines non-statin lipid-lowering drugs, including fibrates, niacin, omega-3 fatty acids, ezetimibe, and bile acid sequestrants. It details their cardiometabolic effects to aid in managing lipid abnormalities.

Area of Science:

  • Pharmacology
  • Cardiology
  • Metabolic Syndrome

Background:

  • Statins are primary agents for reducing cardiovascular risk.
  • Non-statin lipid-lowering drugs improve lipid parameters but their clinical outcome impact is less clear.
  • Limited data exists on the cardiometabolic effects of non-statin lipid-lowering agents.

Purpose of the Study:

  • To review the cardiometabolic profile of non-statin lipid-lowering agents.
  • To compare cardiometabolic effects of various non-statin lipid-lowering drugs.
  • To inform clinical decision-making in lipid abnormality management.

Main Methods:

  • Literature review of studies on non-statin lipid-lowering agents.
  • Analysis of cardiometabolic effects reported in clinical trials and observational studies.
  • Synthesis of data on fibrates, niacin, omega-3 polyunsaturated fatty acids, ezetimibe, and bile acid sequestrants.

Main Results:

  • Non-statin agents exhibit varied cardiometabolic effects.
  • Fibrates and niacin show potential benefits in certain metabolic parameters.
  • Ezetimibe and bile acid sequestrants have a generally neutral cardiometabolic profile.

Conclusions:

  • Understanding the cardiometabolic effects of non-statin lipid-lowering agents is crucial for comprehensive patient care.
  • These agents offer alternative or adjunctive strategies for lipid management.
  • Further research is needed to fully elucidate long-term cardiometabolic outcomes.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324